

Sponsor / Curative Therapy	Clinical Phase and ID	What's going on?
Alseres Cethrin BA-210 in Complete Acute, Cervical and Thoracic SCIs.	Phase I/II Completed NCT00500812	Recruited at 8 locations in the US and Canada. Motor recovery trial suggests BA-210 may increase neuro recovery. Further clinical trials planned, Michael J. Fehlings, MD, PhD-PI, Canada.
Cairo University Autologous Bone Marrow Transplant for Chronic SCIs with a duration of injury from 10 months to 3 years.	Phase II Completed NCT00816803	Recruited at—Cairo University School of Medicine Cairo, Egypt.
International Stemcell Services Ltd. Trans. Autologous BMSC with Glial Scar Resection, Chronic, Acute, Subacute.	Phase I/II Completed NCT01186679	Recruited at—Sita Bhateja Speciality Hospital Bangalore, Karnataka, India Dr.Arvind Bhateja, MCh– PI
StemCells, Inc. HuCNS-SC in Thoracic T2-T11 SCIs, greater than 6 weeks post injury and evidence of conus function.	Phase I/II NCT01321333	Recruiting at—Balgrist University Hospital, Zurich, Switzerland Armin Curt, MD-PI
China SCI Network Umbilical Cord Blood Mononuclear Cell and Lithium in Acute and Chronic SCIs.	Phase I/II NCT00517374, NCT00592722...	Multi center in China.CN100 Observational.CN101&CN102A Lithium PhI/II Completed.CN102B UCBMNCs&Li PhII, Ongoing.CN103 UCBMNCs&Li PhIII Planned early '12 W.Young MD,Phd-Dir.
Proneuron Biotechnologies-ProCord Autologous Incubated Macrophages in Complete, Acute C5-T11 SCIs.	Phase II Suspended NCT00073853	PhI in Belgium and Israel. 50 enrolled between 2003 and 2006. Trial suspended for financial reasons. Study Directors: D. Lammertse, M.D., Nachshon Knoller, M.D., Marca Sipski, M.D., Edward Benzol, M.D.
Translational Research Informatics Ctr. Bone Marrow Stromal Cell Transplant in Acute SCIs.	Phase II Completed NCT00695149	Recruited at—Kansai Medical University Moriguchi, Osaka, Japan
California Stem Cell, Inc. Motorgraft Safety Study Stem Cell-derived Motor Neuron Transplantation for SMA-Type 1	Phase I On Hold	Hans Keirstead Research Group, University of California Irvine - Orphan Drug Status granted in 2009 Feb. 7, 2011 - FDA requested additional animal study and completion of ongoing SMA animal studies.
Geron Corporation Injection of hESC-Derived GRNOPC1 in Complete, T3-T10 SCIs, 7-14 days post injury.	Phase I NCT01217008	Rec. Santa Clara Valley Med.Ctr.,CA- G.Steinberg,MD PhD-PI Shepherd Ctr.,Atlanta,GA-D.Apple,MD-PI Northwestern Univ.Med.Ctr.,Chgo.,IL-R.Fessler,MD PhD-PI Th.Jeff.Univ.Hosp.Phil.,PA- J. Harrop MD-PI
Hospital São Rafael Autologous Bone Marrow Cell Transplantation in Complete, Thoracic and Lumbar SCIs.	Phase I NCT01325103	Recruiting at – Hospital São Rafael, Salvador, Bahia, Brazil - Ricardo R. dos Santos, MD, PhD – PI
Methodist Hospital System Pharmacokinetics of Riluzole in Acute, C4-T12 SCIs.	Phase I NCT00876889	Rec. at 6 US hospitals and 1 hospital in Canada. Approved ALS under brand Rilutek. SCI preclinical studies showed neuroprot. effect. Numerous ongoing clinical trials for various conditions with this drug.
Novartis Pharmacokinetics of Intrathecal Administered AT1355 Anti-Nogo in Complete C5 to T12, Acute SCIs.	Phase I NCT00406016	Recruiting at– Multi center sites in the US, Canada, Germany, Spain, Switzerland Robert Grossman, MD-PI
TCA Cellular Therapy LLC Intrathecal Infusion BMSC in Complete, below C5, Subacute & Chronic SCIs.	Phase I NCT01162915	Recruiting — TCA - Covington, LA —Gabriel P. Lasala, MD-PI
The Miami Project Therapeutic Hypothermia (ARTIC) in Acute Cervical SCIs.	Phase I Completed	NIH Neurologic Emergency Treatment Trials revised proposal to be submitted. Multi center Hypothermia Trial (ARTIC) Ph II study, 17 centers, 210 patients rand. for normothermic vs hypothermic treatment.
Wroclaw Medical Univ. Autologous Olfactory Ensheathing Cells in Complete C5 to L5, Subacute and Chronic SCIs.	Phase I NCT01231893	Recruiting at– Departatment of Neurosurgery at Wroclaw Medical University, Wroclaw, Poland—Pawel Tabakow MD, PhD-PI
InVivo Therapeutics Biocompatible Polymer Scaffolding in Acute SCIs.	IND Application	Investigational Device Exemption (IDE) Application currently being reviewed by the FDA.
Neuralstem, Inc. Human Clinical Trial With Stem Cells in Chronic SCIs.	IND Application	Investigational New Drug (IND) Application currently under review by the FDA. Currently conducting ALS clinical trial - Jonathan Glass, MD-PI
The Miami Project Human Schwann Cell Transplantation in Acute, Severe SCIs.	Preparing IND	Preparing IND. Proposed application date July 2011. This Ph 1 trial will be a dose escalation safety in 9-12 patients.
APINME Assoc. Bone Marrow Stromal Cells in Comp. Thoracic, Chronic SCIs.	Pending Trial	Recruiting at – Hospital University Puerta de Hierro, Madrid, Spain Dr. Vaquero-PI
Spinal Cord Society of New Zealand Transplant Olfactory Ensheathing Cells (OECs)	Pending Trial	Jim Faed, MD – Clinical Research Director